Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Simcere Pharmaceutical Group Days Payable?
Simcere Pharmaceutical GroupSMHGF 72 Days Payable is 54.13 as of Dec. 2025, which is 43% below its 10-year median of 94.95. GuruFocus rates SMHGF with a GF Score™ of 72/100 and a GF Value™ of $1.31 (Fairly Valued). Among 926 Drug Manufacturers companies, Simcere Pharmaceutical Group ranks worse than 70.73% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's Days Payable falls into.
Simcere Pharmaceutical Group Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group (SMHGF) has a Days Payable of 54.13 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Simcere Pharmaceutical Group and its competitors. This is 43% below median its historical median of 94.95. Over the past decade, Simcere Pharmaceutical Group's Days Payable has ranged from 54.44 to 133.91. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #655 out of 926 companies in the Drug Manufacturers industry, placing it in the top 70.7%.
Is Simcere Pharmaceutical Group's Days Payable too high?
Simcere Pharmaceutical Group's current Days Payable of 54.13 is 43% below median its 10-year median of 94.95. Over the past 10 years, this metric has ranged from a low of 54.44 to a high of 133.91. The Drug Manufacturers industry median Days Payable is 88.75. Simcere Pharmaceutical Group's value of 54.13 is 39% below this industry median. Based on the distribution chart, Simcere Pharmaceutical Group ranks #655 out of 926 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Simcere Pharmaceutical Group has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #655 out of 926 companies for Days Payable. This places Simcere Pharmaceutical Group in the lower half of its industry. The industry median Days Payable is 88.75. Simcere Pharmaceutical Group's value of 54.13 is 39% below this benchmark. Historically, Simcere Pharmaceutical Group's own Days Payable has ranged from 54.44 to 133.91 over the past decade. While the company's 10-year median is 94.95 vs. the industry median of 88.75, Simcere Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.75, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simcere Pharmaceutical Group's current Days Payable of 54.13 is 39% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Simcere Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current Days Payable is 54.13, which is 43% below median its own 10-year median of 94.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (SMHGF) is currently considered Fairly Valued. The stock's GF Value™ is $1.31, compared to a current price of $1.35 — trading 3.1% above its estimated fair value. The current Days Payable is 54.13, which is 43% below median its 10-year median of 94.95 and 39% below the Drug Manufacturers industry median of 88.75. Simcere Pharmaceutical Group's overall GF Score™ is 72/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Simcere Pharmaceutical Group (SMHGF), the current Days Payable is 54.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (SMHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.35 is trading 3.1% above its estimated GF Value™ of $1.31.
GuruFocus considers Simcere Pharmaceutical Group to be Fairly Valued.
Key valuation signals for SMHGF:
Days Payable: 54.13 (43% below median its 10-year median of 94.95)
GF Value™: $1.31 vs. price of $1.35 (3.1% above fair value)
Industry Position: 39% below the Drug Manufacturers median (#655 of 926)
No single metric tells the full story. See the SMHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
72GF Score
Get the complete analysis for SMHGF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMHGF has been successfully added to your 
